Table 1.
Identification and Preliminary characterization of SARS-CoV-2 monoclonal antibodies (hybridoma culture supernatants).
| SARS-CoV-2 mAbs | Characterization methods |
||||||
|---|---|---|---|---|---|---|---|
| ELISA (O.D) (1/4 dilution of culture supernatants) |
Western-blot | Isotype | Surrogate Virus Neutralization Test (sVNT) (% of positive control) | Plaque Reduction Neutralization Test (PRNT) | |||
| rSP (100ng/well) | rNP (100ng/well) | Formalin inactivated Virus (5 × 104 pfu/well) | |||||
| F457G1 | 2.03 | 0.07 | 0.45 | rSP | IgG1/k | 8% | Negative |
| F457G2 | 0.07 | 1.59 | 0.87 | rNP | IgG1/k | 1% | Negative |
| F457G3 | 0.08 | 1.79 | 0.91 | rNP | IgG1/k | 5% | Negative |
| F457G4 | 2.22 | 0.07 | 0.24 | rSP | IgG1/M/k | 14% | Negative |
| F457G5 | 0.07 | 0.07 | 0.48 | N | IgG1/k | 4% | Negative |
| F457G6 | 0.07 | 0.88 | 0.53 | rNP | IgG1/k | 1% | Negative |
| F457G7 | 0.07 | 0.07 | 0.35 | N | IgG1/k | 11% | Negative |
| F457G8 | 2.01 | 0.07 | 0.43 | rSP | IgG1/k | 4.3% | Negative |
| F457G9 | 0.08 | 1.18 | 0.62 | rNP | IgG1/k | 1% | Negative |
| F457G10 | 0.08 | 1.31 | 0.54 | rNP | IgG1/k | 1% | Negative |
| F457G11 | 0.08 | 0.07 | 0.34 | N | IgG1/k | 93% | Negative |
| F457G12 | 0.08 | 1.39 | 0.58 | rNP | IgG1/k | (2.62% | Negative |
| F458G1 | N | 0.73 | 0.24 | rNP | IgG1/k | 15.26% | Negative |
| F459G1 | 1.69 | N | N | rSP | IgG2a/k | 97% | PRNT50: ≥640; PRNT90: 80 |
| F459G2 | 2.68 | N | N | rSP | IgG2b/k | 6.44% | Negative |
| F459G3 | 2.9 | N | N | rSP | IgG2a/k | 11.71% | Negative |
| F459G4 | 0.56 | N | N | rSP | IgG1/k | 10.69 | Negative |
| F459G5 | 0.6 | N | N | rSP | IgG1/k | 5.72% | Negative |
| F459G6 | 0.5 | N | N | rSP | IgG2b/k | 7.66% | Negative |
| F459G7 | 0.07 | 2.3 | N | rNP | IgG1/k | 14.48% | Negative |
| F459G8 | 2.1 | N | N | rSP | IgG2b/k | 11.22% | Negative |
| F459G9 | 3.2 | N | N | rSP | IgG1/k | 6.6% | Negative |
| F459G10 | 1.35 | N | N | rSP | IgG1/k | 10.88% | Negative |
| F459G11 | 1.29 | N | N | rSP | IgG1/k | 15.77% | Negative |
| F459G12 | 0.76 | N | N | rSP | IgG1/k | 15.92% | Negative |
| F459G13 | 0.73 | N | N | rSP | IgG1/k | 4.44% | Negative |
| F459G14 | 1.59 | N | N | rSP | IgG1/k | 7.7% | Negative |
| F461G1 | 3.2 | N | N | rSP | IgG1/k | 3.8% | N |
| F461G2 | 3.2 | N | N | rSP | IgG1/k | 2.8% | N |
| F461G3 | 1.28 | N | N | rSP | IgG1/k | 0.48% | N |
| F461G4 | 3 | N | N | rSP | IgG2a/k | 8.71% | N |
| F461G5 | N | 3.5 | N | rNP | IgG2a/λ | 7.67% | N |
| F461G6 | N | 3.4 | N | rNP | IgG1/k | 5.55% | N |
| F461G7 | N | 3.5 | N | rNP | IgG1/k | 6.61% | N |
| F461G8 | 1.00 | N | N | rSP | IgG1/k | 87% | PRNT50: 160; PRNT90: negative |
| F461G9 | 0.47 | N | N | rSP | IgG1/k | 15.7% | N |
| F461G10 | 3.3 | N | N | rSP | IgG2a/k | 3.18% | N |
| F461G11 | 1.10 (1/2 dilution) | rSP | IgG1/k | 92% | PRNT50: 160; PRNT90: 20 | ||
| F461G12 | N | 2.8 | N | rNP | IgG1/λ | 6.55% | N |
| F461G13 | N | 3.3 | N | rNP | IgG1/k | 2.18% | N |
| F461G14 | 2.94 | N | N | rSP | IgG1/M/k | 93% | PRNT50: 40; PRNT90: negative |
| F461G15 | 1.18 | N | N | rSP | IgG1/k | 94% | PRNT50: 80; PRNT90: 20 |
| F461G16 | 1.33 | N | N | rSP | IgG1/k | 93% | PRNT50: 80; PRNT90: negative |
| F461G17 | 2.13 | N | N | rSP | IgG2b/M/k | 31% | Negative |
N: no test or not available; rSP: recombinant spike protein; rNP: recombinant nucleoprotein; Negative: below detection limit.